Table 3.
Achieved/analyzed patients (n) | Eradication rate (95%CI) | P value1 | |
Per protocol | 0.351 | ||
PAC (n = 31) | 27/31 | 87.1% (75.3-98.9) | |
PAM (n = 24) | 22/24 | 91.7% (80.6-100) | |
Sequential (n = 25) | 20/25 | 80.0% (64.3-95.9) | |
Concomitant (n = 10) | 7/10 | 70.0% (34.8-93.3) | |
Intent-to-treat | 0.657 | ||
PAC (n = 36) | 27/36 | 75.0% (60.9-89.1) | |
PAM (n = 27) | 22/27 | 81.5% (66.8-96.1) | |
Sequential (n = 25) | 20/25 | 80.0% (64.3-95.9) | |
Concomitant (n = 11) | 7/11 | 63.6% (35.2-92.1) |
P-value of χ2 test. PAC: Rabeprazole, amoxicillin and clarithromycin; PAM: Rabeprazole, amoxicillin and metronidazole.